Featured Insight
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
On-Demand Webinar – SDOH and EHR – How are EHR vendors enabling providers’ efforts to close care gaps attributable to SDOH?
In this 1 hour live webinar, Precision experts Thad Nowakowski, Tim Van Aken, and Maureen Hennessey discuss the role that Social Determinants of Health plays in contributing to care gaps, current or proposed quality measures to support health equity, and how the top EHR vendors are enabling end user’s efforts to both capture SDOH variables, and act upon them to close care gaps.
On-Demand Webinar – Trends in Oncology: US Payer Management Considerations for 2022 and Beyond
In the last five years, 83 novel oncology substances have launched - oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
A Focus on the Inflation Reduction Act
Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach
Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights. Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.
White Paper: 2022 and Beyond: How Key Legislative Events Will Impact the Payer Landscape
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
Download Now: Precision October Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision September Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
CMS’s Current and Proposed Actions to Bend the Prescription Drug Cost Curve
PRECISIONvalue's Dorothy Agyemang and Elizabeth Oyekan do a deep dive into some of CMS’s current and proposed actions, focusing on both offense and defense tactics to address the rising costs of drugs.
White Paper: 2022 and Beyond: How Key Legislative Events Will Impact the Payer Landscape
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
MM&M’s Top 100 North American healthcare agencies of 2022
We are happy to announce that PRECISIONvalue has made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
Employers and Benefits Consultants Assess Gene Therapy Costs and Solutions
Our employer expert Jorge Font addresses concerns about the increasing numbers of “seven-figure costs” associated with emerging gene therapy and some of the considerations undertaken to address these rising costs.
Court Decision on Accumulator Rule Could Encourage State Bans
A federal court recently struck down a CMS final rule slated to take effect in 2023 which would have required pharmaceutical manufacturers to ensure that financial assistance provided to patients goes only to patients and not to payers under their copay accumulator and maximizer programs. Despite the ruling, Precision's Ryan Cox and Reta Mourad discuss how the renewed attention to these programs could spur more states to take action of their own against them.
Diabetes Cure or Diabetes Management?
Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.
Removal of the Medicaid Rebate Cap: Sensible or Nonsense?
The American Rescue Plan of 2021 introduced a provision to remove the Medicaid Rebate Cap of 100%, effective January 2024. This legislation may turn profits upside down for a pharmaceutical company with a significant presence. Precision's Cynthia Miller discusses what it would mean to remove the Medicaid Rebate Cap, how it would affect pharmaceutical companies, and strategies for moving forward.
‘Alexa, I want to talk to a doctor’: Amazon, Teladoc partner on virtual care
In the most recent Big Tech foray into digital healthcare, Amazon and Teladoc Health announced they will be partnering on a program to provide virtual medical care. Users of Amazon’s Alexa-enabled devices will now be able to contact a doctor via voice command about non-emergency conditions on a 24/7 basis. Precision's Cynthia Miller weighs in on the benefits and shortfalls, including access problems in marginalized communities and rural areas.
Bringing Social Determinants of Health to Life to Optimize Health Outcomes in Patients With Chronic Conditions
As the United States and the world have seen firsthand how social determinants of health (SDOH) impact the mortality and morbidity of patients contracting the COVID-19 virus, addressing SDOH has become a national priority in health care. Organizations nationwide are increasingly looking to integrate SDOH and health equity into value-based strategies.
Within Innovative Oncology Space, Companies Need to Address Oncologists’ Needs
The oncology space is undergoing a tremendous amount of innovation, as novel new products and practices become available. But those treatments can do only so much good if oncologists aren’t using them. Precision's Christy Banach and Janet Serluco weigh in on the opportunity biopharma companies have to differentiate themselves from their competitors by addressing oncologists’ specific needs.
Rethinking Diabetes Care in the Digital Age
In 2021, NCQA and HL7 hosted the fifth annual Digital Quality Summit (DQS) that convened stakeholders within six distinct “tracks” – each track exploring a different subset of healthcare. PRECISIONvalue's Dominic Galante, MD, Jorge Font, MPH, and Maureen Hennessey, PhD, provided consultation to the Helmsley Charitable Trust, sponsors of the Track 6 “Rethinking Diabetes Care in the Digital Age.” Dr. Hennessey and Michael Barr, MD, of NCQA served as track co-leaders.
Pharma Industry Aims to Expand Its Role in Addressing Social Determinants of Health
From federal lawmakers to pharmaceutical companies, plans, providers and other health care stakeholders, efforts are coalescing to address social determinants of health (SDOH). Initiatives are ramping up in response to COVID-19’s disparate impact on vulnerable populations and communities across the U.S. and include pharma collaborations with payers and health systems focusing on social determinants relevant to medication adherence and access.
